05:00 PM EDT, 04/15/2024 (MT Newswires) -- ORIC Pharmaceuticals ( ORIC ) said late Monday it dosed the first patients in three dose expansion groups in a phase 1b trial of ORIC-114 in people with lung cancer.

The phase 1b expansion part of the study will assess the safety and efficacy of the candidate drug at the provisional recommended phase 2 dose levels of 80 milligrams and 120 milligrams per day in people with mutated non-small cell lung cancer, the company said.

The company expects to release phase 1b results in H1 2025.